Imricor Medical Systems (ASX:IMR) said all technical goals of the sensing and image-guided neurological therapies, cardiac electrophysiology, and tumor Treatments consortium related to its NorthStar 3D mapping system operating on Philips Medical Systems' MRI platform were achieved during testing, according to a Thursday filing with the Australian Securities Exchange.
The testing was conducted over 14 hours at Amsterdam University Medical Center on Oct. 10, the filing said.
Philips and the company are now working on full commercialization efforts for NorthStar on the Philips platform, according to the filing.
Imricor Medical Systems' shares rose 8% in morning trade Friday and earlier hit their highest since January 2022.
Price (AUD): $0.80, Change: $+0.060, Percent Change: +8.11%
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。